Biological response modifiers and chemotherapeutic agents that alter interleukin 2 activities.
IL2 immunotherapy alone or with LAK cells represents a novel approach to the treatment of metastatic cancers. Similarly, other BRMs and classical chemotherapeutic drugs through their molecular effects on the components of the immune system reveal new and exciting prospects for the better use of these agents. Both approaches converge in that they restore balance among numerous components of the immune surveillance system. This review raises the possibility of improved protocols through the judicious use of these agents and stresses the need for further investigation of combined use of chemotherapy and immunotherapy.
Howard University College of Medicine, Washington, D.C.
W L
WL
West
A R
AR
Rhoads
C O
CO
Akogyeram
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D054713:Bryostatins; D003520:Cyclophosphamide / Q000494:pharmacology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000494:pharmacology*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D007783:Lactones / Q000494:pharmacology; D007978:Levamisole / Q000494:pharmacology; D018942:Macrolides; D009842:Oligopeptides / Q000494:pharmacology
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D054713:Bryostatins; D007155:Immunologic Factors; D007376:Interleukin-2; D007783:Lactones; D018942:Macrolides; D009842:Oligopeptides; D007978:Levamisole; C046785:bryostatin 1; D003520:Cyclophosphamide; C039537:heptanoyl-gamma-D-glutamyl-L-meso-diaminopimelyl-D-alanine